Protea Biosciences announced this week that it has concluded an exclusive, worldwide license agreement with George Washington University for commercial rights to a new mass spectrometry technology for in situ tissue and cell analysis called laser ablation electrospray analysis, or LAESI.

In a statement, Protea said it will develop instrumentation and software "that will bring the capabilities of the LAESI technology to research laboratories worldwide, beginning in 2011."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.